#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 144 Filer Information Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

# 144: Filer Information

Filer CIK 0001752461 Filer CCC XXXXXXXX Is this a LIVE or TEST Filing? LIVE Submission Contact Information

Name Phone E-Mail Address

## 144: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

### **144: Securities Information**

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	3418	5434.62	60079778	01/21/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

# 144: Securities To Be Sold

Title of the Name of Person Is Date you Nature of Date Amount of Date of Nature of Class Acquired Acquisition from Whom Donor Payment Payment \* this Securities Transaction Acquired Acquired Acquired

Acumen Pharmaceuticals, Inc. 925-368-8508

001-40551 427 PARK ST. **CHARLOTTESVILLE** VIRGINIA 22902

Meisner Derek M

Officer

	Gi	ift?	
Vesting of	Acumen	3418	Granted as part of
Common Stock 01/17/2025 restricted stock	Pharmaceuticals, 🔲		01/17/2025 issuer equity
unit award	Inc.		compensation plan

a

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	<b>Gross Proceeds</b>
Derek Meisner 427 PARK ST. CHARLOTTESVILLE VA 22902	Common Stock	01/03/2025	11122	20506.14

### 144: Remarks and Signature

Remarks	
Date of Notice	01/21/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/15/2024
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature Derek Meisner

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)